

CITATION REPORT

List of articles citing

Cardiovascular effects of phosphodiesterase type 5 inhibitors

DOI: 10.1111/j.1743-6109.2008.01107.x
Journal of Sexual Medicine, 2009, 6, 658-74.

Source: <https://exaly.com/paper-pdf/45991268/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Avanafil: a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. <i>Aging Health</i> , 2010 , 6, 599-605		
39	Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. <i>European Urology</i> , 2010 , 57, 804-14	10.2	722
38	How does chronic sildenafil prevent vascular oxidative stress in insulin-resistant rats?. <i>Journal of Sexual Medicine</i> , 2010 , 7, 79-88	1.1	8
37	Cardiovascular aspects of sexual medicine. <i>Journal of Sexual Medicine</i> , 2010 , 7, 1608-26	1.1	80
36	Nitric oxide-induced vasorelaxation in response to PnTx2-6 toxin from Phoneutria nigriventer spider in rat cavernosal tissue. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3879-88	1.1	19
35	Sexual activity and erectile dysfunction in elderly men with angiographically documented coronary artery disease. <i>International Journal of Impotence Research</i> , 2010 , 22, 40-4	2.3	12
34	Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1427-37	5.9	61
33	[Sexual dysfunction in the elderly. Pathophysiological and medical issues. Treatment of erectile dysfunction]. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2010 , 45, 343-9	1.7	
32	Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. <i>Pharmacological Reviews</i> , 2011 , 63, 811-59	22.5	213
31	Future prospects in the treatment of erectile dysfunction: focus on avanafil. <i>Drug Design, Development and Therapy</i> , 2011 , 5, 435-43	4.4	14
30	Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study. <i>International Journal of Clinical Practice</i> , 2011 , 65, 797-806	2.9	13
29	A fully validated method for the determination of vardenafil in blood using gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2011 , 46, 71-6	2.2	8
28	Beneficial effect of vardenafil on aortic stiffness and wave reflections. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1215-21	2.9	8
27	Vardenafil ameliorates calcium mobilization in pulmonary artery smooth muscle cells from hypoxic pulmonary hypertensive mice. <i>Archives of Medical Research</i> , 2012 , 43, 265-73	6.6	4
26	10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. <i>Journal of Sexual Medicine</i> , 2012 , 9, 265-70	1.1	31
25	Erectile dysfunction and its association with metabolic syndrome and endothelial function among patients with type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2012 , 26, 141-7	3.2	36
24	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 475-83	4.7	42

23	Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension. <i>Redox Biology</i> , 2013 , 1, 578-85	11.3	28
22	Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders. <i>Nephro-Urology Monthly</i> , 2013 , 5, 949-54	0.4	
21	Erectile dysfunction in the cardiovascular patient. <i>European Heart Journal</i> , 2013 , 34, 2034-46	9.5	117
20	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. <i>International Journal of Applied & Basic Medical Research</i> , 2013 , 3, 84-7	1.1	14
19	Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladder. <i>BJU International</i> , 2013 , 112, 246-57	5.6	12
18	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2013 , 31, 83-102	6.8	22
17	Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 701-11	2.9	13
16	Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 53-64	2.6	17
15	Association of Total Atherosclerotic Burden with Progression of Penile Vascular Disease. <i>Journal of Mens Health</i> , 2014 , 11, 44-49	1.2	
14	The Circle of Lifestyle and Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , 2015 , 3, 169-182	5.6	10
13	Acute effect of sildenafil on inflammatory markers/mediators in patients with vasculogenic erectile dysfunction. <i>International Journal of Cardiology</i> , 2015 , 182, 98-101	3.2	24
12	Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. <i>International Journal of Clinical Practice</i> , 2016 , 70, 244-53	2.9	58
11	Sexual dysfunction, cardiovascular risk factors, and inflammatory biomarkers in women undergoing coronary angiography. <i>Journal of Women and Aging</i> , 2016 , 28, 203-10	1.4	4
10	The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. <i>Research in Social and Administrative Pharmacy</i> , 2019 , 15, 591-599	2.9	3
9	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. <i>Mechanisms of Ageing and Development</i> , 2020 , 190, 111311	5.6	4
8	Perception of the association between erectile dysfunction and cardiovascular disease among Chinese physicians: an online survey. <i>Journal of International Medical Research</i> , 2020 , 48, 300060519894187	1.4	0
7	Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	7
6	Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. <i>World Journal of Diabetes</i> , 2017 , 8, 104-111	4.7	29

- 5 Levitra: multiple action, prospects for application. *Problemy Endokrinologii*, **2011**, 57, 30-34 ○
- 4 Stable Ischemic Heart Disease. **2012**, 1210-1269
- 3 Phosphodiesterase-5 Inhibitors in Cardioprotection. **2013**, 439-458
- 2 The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone—*Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery*, **2015**, 31, 157-183 ○
- 1 Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. *Current Vascular Pharmacology*, **2021**, 19, 301-312 3:3 2